log in
Print | Back

Morris, Manning & Martin, LLP

Ping Wang

Ping Wang

Partner

Expertise

  • Corporate
  • Healthcare
  • Intellectual Property
  • Intellectual Property Litigation

WSG Practice Industries

Activity

WSG Leadership

ABA Group
Member
Profile
Dr. Ping Wang is a Partner in the firm’s Intellectual Property Practice. Her practice focuses on all aspects of intellectual property, including patent prosecution, inter partes review, post grant review, interference practice, counseling, and opinions regarding patentability, patent invalidity, freedom-to-operate, infringement, design around, and diligence work in connection with mergers and acquisitions in the biotechnology industry. Dr. Wang also handles patent interferences, patent infringement and other litigation matters, licensing negotiations, technology and academic agreements, acquisitions of capital for entrepreneurs, start-ups, and institutions.

For seven consecutive years, Dr. Wang has been named among the world’s leading patent practitioners in IAM Patent 1000, the top worldwide guide to leading patent professionals and firms. She was the recipient of the Elliot Stellar Award from the Philadelphia Chapter, Society for Neuroscience, and the Lapides Award given by the American Urological Society.

Dr. Wang has extensive experience working with international companies, especially negotiating and handling business between the United States and China.

Bar Admissions

District of Columbia, 2001
State of Maryland, 2000
U.S. District Court for the District of Maryland
U.S. Patent and Trademark Office

Education

Franklin Pierce Law Center, J.D., 1999
Kunming Medical College, M.D., 1986
Areas of Practice

Corporate | Healthcare | Intellectual Property | Intellectual Property Litigation | Patents/Trademarks/Copyrights | Technology

Professional Career

Significant Accomplishments

2019 Intellectual Property Trailblazer, National Law Journal, March 2018
Named “One of the World’s Leading Patent Practitioners” for Patent Prosecution in Washington, D.C., Intellectual Asset Management Magazine’s IAM Patent 1000: The World’s Leading Patent Practitioners, 2012-2014, 2016, 2017
Profiled as one of the leading Patents: Licensing, and Patents: Prosecution lawyers in the United States, The U.S. Legal 500, 2017
American Bar Association
American Intellectual Property Law Association
American Health Law Association
American International Law Association
Member, American Intellectual Property Law Association, Interference Committee, Biotechnology Committee, and Licensing Committee
United States Patent and Trademark Office, Biotechnology, Chemical, and Pharmaceutical Partnership
Society for Neuroscience
International Brain Research Organization

Professional Associations

  • American Bar Association
    American Intellectual Property Law Association
    American International Law Association
    American Health Law Association
    International Brain Reserach Organization

Member, American Intellectual Property Law Association, Interference Committee, Biotechnology Committee, and Licensing Committee
United States Patent and Trademark Office, Biotechnology, Chemical, and Pharmaceutical Partnership Society for Neuroscience


Seminars

Invited plenary speaker: How to Protect Computer Software Related Intellectual Property Rights in the US. China Computer Software Association, Shandong, China (2002)

Articles

Gene Therapy Policies Can Strike An Ethical Balance
Morris, Manning & Martin, LLP, July 2018

On July 11, 2018, then-U.S. Food and Drug Administration Commissioner Scott Gottlieb made a public statement about the agency’s efforts to advance the development of gene therapies.[1] Gottlieb pointed out that the FDA has approved three separate gene therapy products and the agency has issued six scientific guidance documents intended to serve as building blocks of a modern, comprehensive framework for how the FDA can advance the field of gene therapy...

Additional Articles

“New Proposed Rules Regarding Government Rights in Federally Funded Research,” February 21, 2017

“Best Practices in Oral Argument in an Inter Partes Review Hearing,” July 29, 2015; Republished by IP Litigator (Wolters Kluwer), September/October, 2015

“The Federal Circuit Clarifies the Steps in the Biosimilars Dance,” July 24, 2015

“The Presumption of Validity Triumphs over a Good-Faith Belief of Invalidity,” May 28, 2015

“Post Exclusivity Issues For Biologics,” December 22, 2014

“The Myriad Decision in the U.S. Supreme Court IP and Technology Developments,” Special Edition, BIO Conference, July 10, 2012

“Is an Isolated DNA Patentable?” IP and Technology Developments, October 25, 2011

Luthin, G.R., Wang, P., Zhou, H., Dhanasekaran, D., and Ruggieri, M.; Role of m1 receptor-G Protein coupling in cell proliferation in the prostate. Annals of the N.Y. Academy of Sciences, Vol. 160, Nos. 13/14, 1997

Tian, X.H., Gu, J.F., Sun, C.P., and Wang, P.; An EPR study of the neuroprotective effect of the sulfated polysaccaride from Laminaria Japonica, Society for Neuroscience, 15: 2187, 1997

Wang, P., Dhanasekaran, N.E., and Luthin, G.R.; ERK activation and cellulary proliferation in response to muscarinic acetylcholine receptor agonist, Annals of the N.Y. Academy of Sciences, 1996

Wang, P., Luthin, G.R., and Ruggieri, M.R.; Muscanrinic acetylcholine receptors mediating urinary bladder contractility and coupling to GTP binding proteins, Journal of Pharmacology Experiments and Therapeutics, 273:959-966, 1995

Wang, P., Dhanasekaran, N.D., and Luthin, G.R.; ERK activation and cellular proliferation in response to muscarinic acetylcholine receptor agonist, Receptor Classification, Verona, Italy, 1995

Ruggieri, M.R., Colton, M.D., Wang, P., Smyth, R.J., Pontari, M.A., and Luthin, G.R.; Human prostate muscarinic receptor subtypes Journal of Pharmacology Experiments and Therapeutics, 274:976-982, 1995

Wang, P., Dhanasekaran, N.D., and Luthin, D.R.; ERK activation and cellular proliferation in response to muscarinic acetylcholine receptor agonist, Receptor Classification, Verona, Italy, 1995

Ruggieri, M.R., Colton, M.D., Wang, P., Smyth, R.J., Ontari, M.A., and Luthin, G.R.; Human prostate muscarinic receptor subtypes studied, American Urological Association Today, 8:1-13, 1995

Wang, P., Luthin, G.R., and Ruggieri; M.R. Muscarinic acetylcholine receptor subtypes mediating urinary bladder contractility and coupling to GTP binding proteins, Journal of Urology, Survey Section, 1995

Wang, P. Ruggieri, M.R., and Luthin, G.R.; Biochemical analysis of urinary bladder muscarinic receptor subtypes, J. Urological, Soc. Basic Urol. Res. Suppl., San Francisco, CA, 1994

Colton, M.D., Wang, P., Cawley, T.A., Luthin, G.R., and Ruggieri; M.R. Effect of experimental hyperreflexia on rabbit bladder muscarinic receptor subtypes, Journal of Urology 151:482A, 1994

Ruggieri, M.R., Colton, M.D., Wang, P., Smyth, R.J., Pontari, M.A., and Luthin, G.R.; Human prostate muscarinic receptor subtypes, J. Urological, 151:380A, 1994

Ruggieri, M.R., Colton, M.D., Wang, P., Smyth, R.J., Pontari, M.A., and Luthin, G.R.; Human prostate muscarinic receptor subtypes, Society for Basic Urological Research, Houston, TX, 1993

Smyth, R.J., Ruggieri, M.R., Colton, M.D., Wang, P., Shickley, T.J., and Luthin, G.R.; Prostate gland contains high levels of the m1 subtype of muscarinic receptor, Society for Neuroscience, 19:1786, 1993

Wang, P., and Luthin, G.R.; Stable association of m3 muscarinic receptors and G proteins, Society for Neuroscience, 19:1768, 1993

Cawley, T.A., Wang, P., Ruggieri, M.R., and Luthin, G.R.; Muscarinic acetylcholine receptors in urinary bladder, Society for Neuroscience, 19:1767, 1993

Ruggieri, M.R., Cawley, T.A., Wang, P., Hicks, S.E., and Luthin, G.R.; Urinary bladder muscarinic receptor subtypes; effect of chronic neuroleptic treatment, Incontinence Society, Halifax, Nova Scotia, 1992


WSG's members are independent firms and are not affiliated in the joint practice of professional services. Each member exercises its own individual judgments on all client matters.

HOME | SITE MAP | GLANCE | PRIVACY POLICY | DISCLAIMER |  © World Services Group, 2020